Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 23 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in PAVM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PAVM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 1, 2026 | Mcgrath Dennis MPresident | Stock Award(Grant) at price 0.00 per share. | 180K | — |
| Apr 1, 2026 | Aklog LishanChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 350K | — |
| Apr 1, 2026 | Glennon Michael JDirector | Stock Award(Grant) at price 0.00 per share. | 13.9K | — |
| Apr 1, 2026 | Agrawal SundeepDirector | Stock Award(Grant) at price 0.00 per share. | 13.9K | — |
| Apr 1, 2026 | White Debra JayneDirector | Stock Award(Grant) at price 0.00 per share. | 13.9K | — |
| Apr 1, 2026 | O'Neil ShaunChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 110K | — |
| Apr 1, 2026 | Baxter Timothy EDirector | Stock Award(Grant) at price 0.00 per share. | 13.9K | — |
| Apr 1, 2026 | Gordon Michael AdamGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 110K | — |
| Apr 1, 2026 | Lee Victoria Tou-HoOfficer | Stock Award(Grant) at price 0.00 per share. | 70K | — |
| Sep 29, 2025 | Mcgrath Dennis MPresident | — | 150K | — |
| Sep 29, 2025 | Aklog LishanChief Executive Officer | — | 150K | — |
| Sep 29, 2025 | Glennon Michael JDirector | — | 150K | — |
| Sep 29, 2025 | Agrawal SundeepDirector | — | 150K | — |
| Sep 29, 2025 | White Debra JayneDirector | — | 150K | — |
| Sep 29, 2025 | O'Neil ShaunChief Operating Officer | — | 150K | — |
| Sep 29, 2025 | Baxter Timothy EDirector | — | 150K | — |
| Sep 29, 2025 | Gordon Michael AdamGeneral Counsel | — | 150K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.9 | 30.1 | 0.7 | -18.2 | -25.3 | -4.2 | -16.7 | 5.3 | -29.2 | -28.5 | −60.2% | ||
| 2025 | 5.7 | 11.4 | -2.6 | 0.6 | -17.1 | -0.2 | -4.0 | -15.8 | -11.1 | -0.5 | -14.0 | -40.1 | −64.8% |
| 2024 | -43.7 | 14.2 | -19.2 | -6.5 | -27.5 | -43.8 | 6.1 | 5.2 | 35.2 | -13.0 | -9.3 | -35.3 | −84.8% |
| 2023 | 6.5 | -9.4 | -19.2 | 17.6 | -8.9 | 1.7 | -7.8 | -16.8 | -5.8 | -11.5 | 18.4 | -11.1 | −42.8% |
| 2022 | -30.1 | -11.0 | -13.7 | -3.8 | -20.5 | -7.4 | 29.4 | -1.7 | -27.7 | 44.2 | -43.5 | -31.4 | −80.5% |
| 2021 | -3.3 | 104.9 | 5.7 | 2.9 | 16.0 | 20.8 | 7.3 | 6.3 | 17.0 | -36.4 | -32.4 | -33.0 | +16.0% |
| 2020 | 23.3 | 68.9 | -20.8 | 10.6 | -9.1 | 6.0 | -5.7 | -1.0 | -9.6 | 0.6 | 8.4 | 9.3 | +76.7% |
| 2019 | 5.5 | -0.5 | 8.9 | 17.3 | -16.3 | 5.6 | -11.4 | -3.0 | -2.1 | -6.3 | -3.3 | 38.1 | +24.7% |
| 2018 | -20.4 | -3.0 | -7.1 | 0.0 | -29.3 | -18.1 | 66.3 | -17.7 | 0.0 | -12.3 | -14.9 | -0.8 | −57.9% |
| 2017 | -2.2 | -8.3 | -19.2 | -2.6 | -13.6 | 7.0 | -22.7 | 23.6 | 26.2 | -18.8 | -32.2 | -23.6 | −66.9% |
| 2016 | 10.0 | -2.1 | -15.7 | -32.2 | -13.8 | −46.9% |
Buy / hold / sell counts
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.